Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.18 - $0.86 $34,009 - $162,491
-188,944 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$0.6 - $1.06 $150 - $266
-251 Reduced 0.13%
188,944 $114,000
Q4 2021

Feb 10, 2022

SELL
$0.85 - $1.4 $3,003 - $4,947
-3,534 Reduced 1.83%
189,195 $171,000
Q3 2021

Nov 12, 2021

BUY
$1.33 - $1.77 $16,970 - $22,585
12,760 Added 7.09%
192,729 $256,000
Q2 2021

Aug 05, 2021

BUY
$1.41 - $1.94 $156 - $215
111 Added 0.06%
179,969 $259,000
Q1 2021

May 06, 2021

SELL
$1.61 - $2.77 $17,999 - $30,968
-11,180 Reduced 5.85%
179,858 $324,000
Q4 2020

Feb 10, 2021

BUY
$1.55 - $2.24 $19,607 - $28,336
12,650 Added 7.09%
191,038 $334,000
Q3 2020

Nov 12, 2020

SELL
$1.91 - $3.08 $57,357 - $92,492
-30,030 Reduced 14.41%
178,388 $348,000
Q2 2020

Aug 13, 2020

BUY
$1.97 - $3.98 $103,389 - $208,878
52,482 Added 33.66%
208,418 $575,000
Q4 2019

Feb 05, 2020

SELL
$1.16 - $1.42 $313 - $383
-270 Reduced 0.17%
155,936 $192,000
Q3 2019

Oct 23, 2019

SELL
$1.21 - $1.65 $496 - $676
-410 Reduced 0.26%
156,206 $208,000
Q2 2019

Aug 14, 2019

BUY
$1.39 - $2.03 $20,466 - $29,889
14,724 Added 10.38%
156,616 $263,000
Q1 2019

May 01, 2019

SELL
$1.39 - $1.71 $3,287 - $4,044
-2,365 Reduced 1.64%
141,892 $213,000
Q4 2018

Jan 31, 2019

BUY
$1.41 - $2.16 $65,656 - $100,580
46,565 Added 47.67%
144,257 $208,000
Q3 2018

Nov 07, 2018

SELL
$1.86 - $2.18 $13,020 - $15,260
-7,000 Reduced 6.69%
97,692 $205,000
Q2 2018

Aug 06, 2018

BUY
$1.76 - $2.79 $28,661 - $45,435
16,285 Added 18.42%
104,692 $206,000
Q1 2018

May 02, 2018

SELL
$1.34 - $2.03 $3,122 - $4,729
-2,330 Reduced 2.57%
88,407 $162,000
Q4 2017

Feb 09, 2018

SELL
$1.65 - $2.45 $34,537 - $51,283
-20,932 Reduced 18.74%
90,737 $164,000
Q3 2017

Nov 06, 2017

BUY
$1.5 - $2.55 $167,503 - $284,755
111,669
111,669 $230,000

About ATHERSYS, INC


  • Ticker ATHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 305,110,016
  • Market Cap $3.05M
  • Description
  • Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...
More about ATHX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.